{"id":"NCT01735175","sponsor":"Sandoz","briefTitle":"Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®","officialTitle":"A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2013-05","completion":"2014-02","firstPosted":"2012-11-28","resultsPosted":"2017-06-15","lastUpdate":"2017-08-07"},"enrollment":316,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Neutropenic Complications","Breast Neoplasms","Chemotherapy-induced Neutropenia","Chemotherapeutic Toxicity"],"interventions":[{"type":"DRUG","name":"LA-EP2006","otherNames":["pegfilgrastim"]},{"type":"DRUG","name":"Neulasta®","otherNames":["pegfilgrastim"]}],"arms":[{"label":"Neulasta®","type":"ACTIVE_COMPARATOR"},{"label":"LA-EP2006","type":"EXPERIMENTAL"}],"summary":"The study will assess the efficacy of LA-EP2006 compared to Neulasta® with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.","primaryOutcome":{"measure":"Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy","timeFrame":"21 days (Cycle 1 of chemotherapy treatment)","effectByArm":[{"arm":"LA-EP2006","deltaMin":0.75,"sd":0.878},{"arm":"Neulasta®","deltaMin":0.83,"sd":0.898}],"pValues":[{"comp":"OG000 vs OG001","p":"0.05"},{"comp":"OG000 vs OG001","p":"0.05"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":41,"countries":["Brazil","India","Mexico","Romania","Russia","Ukraine"]},"refs":{"pmids":["27020170","28637287"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":159},"commonTop":["Alopecia","Nausea","Asthenia","Vomitting","Neutropenia"]}}